ClinicalTrials.gg
RecruitingNCT07219459GDFATHERHCC01Updated Nov 10, 2026

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

A Phase 2 interventional study of Visugromab RDE (recommended dose for expansion) and Nivolumab in Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma and Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound, sponsored by CatalYm GmbH. Recruiting at 29 sites in 7 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by CatalYm GmbH · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 10, 2026First site in Taiwan6 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Planned enrollment
180th of 775
104 · median 36
Started
2026
with 35 others
Phase 2
259 of 926
40 open now
Primary completion
2029-09
later than 209 of 244 live
Registered
894th of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 180th largest by planned enrollment of the 775 interventional ones that give a count, is one of 36 that started in 2026, is one of 259 in phase 2, reaches primary completion later than 209 of the 244 other live ones, and was the 894th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compared to double placebo and Lenvatinib in participants with unresectable or metastatic HCC and compensated liver function (Child-Pugh A) after failure of 1L treatment that included an anti-PD-(L)1 compound. The trial consists of 2 Parts: a non-randomized Safety-run-in part (Part 1) and the subsequent randomized part (Part 2) with 2 treatment arms (A and B). Randomization of participants into Treatment Arm A and B will continue until 40 efficacy-evaluable participants are enrolled into each Treatment Arm.

03

Conditions studied

  • Unresectable or Metastatic Hepatocellular Carcinoma
  • Child-Pugh A Hepatocellular Carcinoma
  • Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

Keywords

  • CTL-002
  • Visugromab
  • GDF-15
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • confirmed diagnosis of unresectable or HCC, not amenable to a curative treatment approach.
  • as per v1.1 as determined by the Investigator based upon local radiologist assessment.
  • Must have failed one line of prior systemic treatment for unresectable or metastatic HCC containing an approved anti PD (L)-1 (CPI) with a minimum treatment duration of 12 weeks exposure for the CPI with no documented progression in this period.
  • Age ≥ 18 years on the day of signing the .
  • of at least 3 months as assessed by the Investigator.
  • performance status ≤1.
  • score of A6 or better.

Main Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma.
  • More than 1 line of prior systemic treatment for unresectable or metastatic HCC.
  • Received or completed any palliative radiotherapy for symptoms within 28 days of the first dose of IMP.
  • Expected to require any other form of antineoplastic therapy during the trial.
  • Clinically active inflammatory bowel disease, active diverticulitis, intra-abdominal abscess, and/or gastrointestinal obstruction.
  • Known history of other prior unless participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
  • Known or detected clinically active central nervous system (CNS) involvement by HCC or other tumors.
  • Have one of the following cardiovascular risk factors: myocardial infarction, peri/myocarditis, or history of ischemic stroke in the past 3 months before planned treatment start, uncontrolled heart failure, uncontrolled ventricular arrhythmia, corrected for heart rate using Fridericia's formula interval ≥ 470 ms regardless of sex.
  • An active disease that has required systemic treatment in past 3 months before planned treatment start.
  • Comedication with metformin or metformin-containing antidiabetics in participants with type II diabetes.
  • Chronic systemic treatment for other reasons.
  • Prior liver or other organ transplantation.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Arm A

    Visugromab (IV) + Nivolumab intravenous (IV) + Lenvatinib (PO)

    Biological: Visugromab RDE (recommended dose for expansion) · Biological: Nivolumab · Drug: Lenvatinib

  • Active comparator
    Arm B

    Lenvatinib (PO) + saline (double-placebo) intravenous (IV)

    Drug: Lenvatinib · Other: Placebo Saline Infusion

Interventions

  • Participants receive visugromab (RDE) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments

    Also known as: CTL-002

  • BiologicalNivolumab

    Participants receive Nivolumab 360mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments after visugromab infusion

    Also known as: OPDIVO®

  • Participants receive Lenvatinib per os (PO) once daily according to body weight (\> 60kg: 12mg; \< 60kg: 8mg)

    Also known as: Lenvima

  • OtherPlacebo Saline Infusion

    Saline (0.9%NaCl) intravenous (2x IV) on Day 1 of every 21-day cycle every 3 weeks (Q3W) for up to 35 treatments

    Also known as: 0.9% NaCl

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Investigator assessed Progression-free survival (PFS) time from randomization (during Safety Run-In: initiation of treatment) to first documented disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death due to any cause, whichever occurred first.

    Time frame: up to 36 months

Secondary outcomes

  1. Independently assessed PFS by Blinded Independent Central Review (BICR)

    Time frame: up to 36 months

  2. CR (Complete Response) rate

    Time frame: up to 36 months

  3. PR (Partial Response) rate

    Time frame: up to 36 months

  4. ORR (Overall Response) rate

    Overall response rate, defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by the Investigator

    Time frame: up to 36 months

  5. TTR (Time-to-response) rate

    Time frame: up to 36 months

  6. PFS (Progression-free survival) rate

    Time frame: up to 36 months

  7. Change in body weight (kg) from baseline

    Time frame: up to 39 months

  8. Adverse Events

    Incidence, type and severity of adverse events, treatment emergent adverse events, treatment-related adverse events and serious adverse events

    Time frame: up to 60 months

  9. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score [0-100]

    Assess participants' subjective wellbeing; higher score means better Quality of Life

    Time frame: up to 39 months

  10. Overall survival (OS)

    Time frame: up to 60 months

Other outcomes

  1. Maximum concentration (Cmax) of visugromab

    Cmax is the maximum observed serum concentration of visugromab

    Time frame: At designated time points (up to 36 months)

  2. Minimum concentration (Cmin) of visugromab

    Cmin is the minimum observed serum concentration of visugromab

    Time frame: At designated time points (up to 36 months)

  3. Functional Assessment of the Anorexia and Cachexia Therapy questionnaire (FAACT-A/CS)

    FAACT-ACS consists of 12 items assessing anorexia/cachexia-related symptoms. Each item is scored individually from 0 ("Not at all") to 4 ("Very much"), with some requiring reverse scoring as in the FAACT Scoring Guideline. The FAACT-ACS subscale score is calculated by summing item scores (reversals performed as applicable); multiplied by the total number of items and divided by the number of items answered. The total score ranges from 0-48, with higher scores indicating better anorexia/cachexia-related quality of life.

    Time frame: up to 39 months

07

Study locations

29 of 29 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2029, 42 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 42 months is above that.

Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2025
First posted
Oct 21, 2025
StartActual
Mar 19, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first site in Taiwan
Show 6 added (2 Taiwan, 1 United States, 1 France, 1 Germany, 1 United Kingdom)
  • UCLA Hematology/Oncology - Santa Monica · Santa Monica, United States
  • Montpellier University Hospital Center - Saint Eloi Hospital · Montpellier, France
  • University Hospital Cologne, Clinic of Gastroenterology and Hepatology · Cologne, Germany
  • Chia-Yi Christian Hospital · Chiayi City, Taiwan
  • Taipei Veterans General Hospital · Taipei, Taiwan
  • The Christie NHS Foundation Trust · Manchester, United Kingdom
Nov 10, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Peidmont Healthcare, Inc · Atlanta, United StatesContact s•••@piedmont.org · •••1777→Z•••@piedmont.org · •••3780Contact k•••@piedmont.org · •••2366→j•••@piedmont.org · •••2366
  • OSF St. Francis Medical Center · Peoria, United StatesContact none listed→•••5013
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    6 sites added — first site in Taiwan
    Show 6 added (2 Taiwan, 1 United States, 1 France, 1 Germany, 1 United Kingdom)
    • UCLA Hematology/Oncology - Santa Monica · Santa Monica, United States
    • Montpellier University Hospital Center - Saint Eloi Hospital · Montpellier, France
    • University Hospital Cologne, Clinic of Gastroenterology and Hepatology · Cologne, Germany
    • Chia-Yi Christian Hospital · Chiayi City, Taiwan
    • Taipei Veterans General Hospital · Taipei, Taiwan
    • The Christie NHS Foundation Trust · Manchester, United Kingdom
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Peidmont Healthcare, Inc · Atlanta, United StatesContact s•••@piedmont.org · •••1777→Z•••@piedmont.org · •••3780Contact k•••@piedmont.org · •••2366→j•••@piedmont.org · •••2366
    • OSF St. Francis Medical Center · Peoria, United StatesContact none listed→•••5013
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07219459
Lead sponsor
CatalYm GmbH
Responsible party
Sponsor
First posted
Oct 21, 2025
Start date
Mar 19, 2026
Primary completion
Sep 2029 (estimated)
Completion
Sep 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Tomáš Janík, MD
Contact
regulatory-005@catalym.com
+49892000664 ext. 31

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Visugromab

Start the discussion